Meeting
2022 ASCO Annual Meeting
Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.
Authors
Thierry Facon
University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
Thierry Facon , Shaji Kumar , Torben Plesner , Philippe Moreau , Nizar J. Bahlis , Hartmut Goldschmidt , Michael O'Dwyer , Aurore Perrot , Christopher P. Venner , Katja Weisel , Joseph R. Mace , Noopur S. Raje , Mourad Tiab , Margaret Macro , Laurent Frenzel , Xavier Leleu , Huiling Pei , Fredrik Borgsten , Saad Zafar Usmani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02252172
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8044)
DOI
10.1200/JCO.2022.40.16_suppl.8044
Abstract #
8044
Poster Bd #
468
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.
First Author: Saad Zafar Usmani
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).
First Author: Pieter Sonneveld
Poster
2019 ASCO Annual Meeting
Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.
First Author: Aurore Perrot